Psilocybin is studied mainly for depression and MDMA for PTSD; neither is FDA-approved, and only psilocybin has licensed US state programs (Oregon and Colorado).
Psilocybin and MDMA are studied for different conditions through distinct pharmacological pathways, and neither compound has received Food and Drug Administration (FDA) approval as of 2026. Psilocybin is primarily researched for major depressive disorder (MDD) and treatment-resistant depression (TRD), whereas 3,4-methylenedioxymethamphetamine (MDMA) has been evaluated specifically for post-traumatic stress disorder (PTSD).
At Mind Medicine Law, we track federal scheduling alongside emerging state frameworks to clarify where supervised administration is lawful and where research remains confined to clinical trials. State-regulated access exists for psilocybin in Oregon and Colorado, while lawful MDMA administration in the United States remains restricted entirely to authorized clinical protocols and individual expanded access programs.
| Factor | Psilocybin | MDMA |
|---|---|---|
| Federal legal status (US) | Schedule I under the federal Controlled Substances Act (CSA); not approved by the FDA for any medical indication. | Schedule I under the federal Controlled Substances Act (CSA); not approved by the FDA for any medical indication. |
| Primary studied condition | Treatment-resistant depression (TRD) and major depressive disorder (MDD). | Post-traumatic stress disorder (PTSD). |
| Pharmacological mechanism | Active metabolite psilocin acts as an agonist at the serotonin 5-HT2A receptor. | Acts as an entactogen by releasing serotonin, dopamine, and norepinephrine. |
| Dosing session length | Single active session lasting 4 to 6 hours with two trained facilitators. | Three separate sessions lasting about 8 hours each, spaced 2 to 4 weeks apart. |
| State-level access programs | Available to adults 21 and older at licensed service centers in Oregon and healing centers in Colorado. | No state-licensed access programs exist in any United States jurisdiction. |
| Primary safety considerations | Receptor blunting from concurrent serotonergic antidepressants and need for supervised tapering. | Elevated blood pressure, raised heart rate, and life-threatening serotonin syndrome risks with serotonergic drugs. |
Psilocybin and MDMA address distinct clinical diagnoses rather than competing for the same psychiatric indication. Clinical researchers study psilocybin primarily as an intervention for major depressive disorder and treatment-resistant depression. MDMA investigation centers on post-traumatic stress disorder.
Psilocybin produces classic psychedelic effects including perceptual changes and an altered sense of self. MDMA reliably produces elevated mood, increased interpersonal trust, and a reduced fear response.
Neither substance serves as an interchangeable substitute for the other in clinical practice.
Psilocybin functions as a classic serotonergic psychedelic, whereas MDMA operates pharmacologically as an entactogen or empathogen. When consumed, psilocybin converts into its active metabolite, psilocin, which activates serotonin 5-HT2A receptors. This receptor activation produces perceptual changes and an altered sense of self.
MDMA does not primarily activate the 5-HT2A receptor to create its therapeutic effects. The compound triggers the release of serotonin, dopamine, and norepinephrine. This release reliably produces elevated mood, increased interpersonal trust, and a reduced fear response.
MDMA-assisted therapy requires a multi-month clinical commitment involving repeated long sessions, while psilocybin protocols generally rely on a single acute dosing day. The Phase 3 MDMA protocol incorporates roughly 12 to 18 therapy contacts over approximately 12 weeks. This schedule consists of three preparatory sessions, three active 8-hour dosing sessions spaced 2 to 4 weeks apart, and three integration sessions.
MDMA dosing sessions use one male and one female co-therapist. Participants receive an initial dose between 120 mg and 180 mg, often followed by an optional supplemental half-dose administered roughly 90 minutes into the session.
Psilocybin depression protocols use a more condensed operational model. Patients participate in two to three preparatory sessions, one active dosing session lasting 4 to 6 hours with two trained facilitators, and subsequent integration discussions. Clinical trials for depression typically administer a single 25 mg dose of synthetic psilocybin, which is roughly equivalent to 5 grams of dried mushrooms.
Clinical trials evaluate psilocybin and MDMA in isolation for separate indications, meaning researchers possess no head-to-head comparison data between the two drugs. In depression research, a 2022 Phase 2b trial sponsored by COMPASS Pathways and published in the New England Journal of Medicine evaluated 233 adults with treatment-resistant depression. The study found that the 25 mg arm produced a larger drop in depression scores at week 3 than the 1 mg control arm, though the between-group difference narrowed by week 12.
The Phase 3 COMP005 trial, registered under NCT05624268 with 258 adult participants suffering from treatment-resistant depression, met its primary efficacy endpoint on June 23, 2025. Patients who received a single 25 mg dose showed a mean reduction of 3.6 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) at week 6 relative to placebo (p<0.001). The sponsor did not report clinical remission percentages in the initial announcement.
MDMA evidence for post-traumatic stress disorder comes primarily from the MAPP1 and MAPP2 Phase 3 trials published in Nature Medicine. In the 2021 MAPP1 trial comprising 90 participants with severe PTSD, 67 percent of patients in the MDMA-assisted therapy group no longer met diagnostic criteria for PTSD after three sessions, compared to 32 percent in the placebo-assisted therapy cohort. The 2023 MAPP2 trial evaluated 104 participants and confirmed this clinical signal, documenting that 71 percent of MDMA participants lost their PTSD diagnosis versus 48 percent receiving therapy with placebo at 18 weeks.
Neither psilocybin nor MDMA has received FDA approval as of 2026, keeping both substances categorized as Schedule I controlled substances under federal law. The FDA granted Breakthrough Therapy designation for psilocybin to COMPASS Pathways in October 2018 for treatment-resistant depression, and to the Usona Institute in November 2019 for major depressive disorder. According to the National Institute on Drug Abuse (NIDA), the FDA has also granted Breakthrough Therapy designation to MDMA for post-traumatic stress disorder.
Breakthrough Therapy status expedites clinical development and regulatory review for investigational compounds that demonstrate substantial improvement over available treatments in preliminary trials, but it does not convey commercial marketing approval.
In August 2024, the FDA issued a Complete Response Letter (CRL) to Lykos Therapeutics declining to approve MDMA-assisted therapy for PTSD. An FDA advisory committee in June 2024 voted against efficacy and benefit-risk (9-2 and 10-1). As summarized in this site's MDMA guide, concerns cited in the Complete Response Letter included functional unblinding, trial-conduct concerns, durability of the effect, and incomplete cardiac and laboratory safety data.
Legal access within the United States exists exclusively for psilocybin through non-medical state programs, while domestic MDMA administration remains restricted to authorized research protocols. Oregon voters approved Measure 109 in November 2020, establishing licensed psilocybin service centers that opened to the public in January 2023. Any adult aged 21 or older can receive supervised psilocybin administration in Oregon without a medical referral or clinical diagnosis.
Colorado approved Proposition 122 in 2022, creating a natural medicine framework that authorized licensed healing centers to dispense psilocybin starting in 2025. Like the Oregon model, Colorado healing centers operate outside healthcare networks, prohibit explicit medical claims, and accept adults aged 21 and older. The service is not covered by insurance, and participants in Oregon typically pay about $1,800 to $3,000 per session.
MDMA lacks any state-level access structure in the United States, confining domestic access to clinical trials or formal FDA Expanded Access allowances for qualifying individuals. Australia is the only country where clinicians can legally prescribe MDMA for post-traumatic stress disorder under the Therapeutic Goods Administration (TGA) Authorised Prescriber scheme introduced in July 2023. Australian access requires individual patient approval and is not covered by Medicare.
MDMA produces acute effects including elevated heart rate, increased blood pressure, jaw clenching, sweating, pupil dilation, and emotional intensity. MDMA is not appropriate for people with uncontrolled cardiovascular disease.
Combining MDMA with selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or tramadol creates a risk of life-threatening serotonin syndrome. Clinical trial protocols require candidates to complete a medically supervised taper from all serotonergic antidepressants before dosing. Phase 3 trial designs also excluded participants with bipolar I disorder, mania, or primary psychotic disorders.
Psilocybin does not form physical dependence, but it requires careful pharmacological management of concurrent medications. SSRIs and SNRIs can blunt psilocybin's effects through SSRI-driven downregulation of the 5-HT2A receptor. Licensed service facilitators and research protocols require a structured, supervised medication taper before administration, though you must never stop a psychiatric prescription abruptly without your prescriber.
If you have bipolar I disorder, mania, or a primary psychotic disorder, trial protocols exclude you.
If you take an SSRI, SNRI, MAOI, or tramadol, you cannot safely undergo MDMA therapy due to serotonin syndrome risks, nor can you experience the full effects of psilocybin without an intentional medication adjustment. If you are unwilling or medically unable to complete a supervised taper under physician direction, you must avoid these therapies until your primary regimen allows modification.
Neither therapy is for you if you plan to self-administer at home or outside a licensed program.
Regulatory decisions by the FDA would fundamentally reshape how clinicians evaluate psilocybin and MDMA. If the FDA accepts Resilient Pharmaceuticals' August 2026 resubmission and approves MDMA for post-traumatic stress disorder, that action would grant formal federal approval.
Similarly, FDA approval of a psilocybin application would establish formal federal approval for medical use. A published head-to-head clinical trial evaluating both substances within the same diagnostic cohort would also alter current guidance by clarifying comparative efficacy and tolerability.
Until then, rely on condition-specific clinical trials or the licensed Oregon and Colorado centers for supervised care.
Psilocybin is the appropriate choice if you are seeking therapy for major depression and live near or can travel to licensed service centers in Oregon or Colorado, or qualify for active clinical trials. MDMA is the appropriate option to explore if you are managing post-traumatic stress disorder, though access remains strictly limited to clinical trial enrollment or Australian medical programs.
If you take an antidepressant, keep taking it until a prescriber plans a taper, and use the clinical-trial finder or the which-psychedelic quiz to see what you can access.
MDMA holds the relevant clinical evidence for post-traumatic stress disorder. Phase 3 trials published in Nature Medicine showed that 67 to 71 percent of participants receiving MDMA-assisted therapy lost their PTSD diagnosis. Psilocybin research focuses primarily on depressive disorders rather than post-traumatic stress.
Psilocybin possesses the documented clinical evidence for depressive disorders. The Phase 3 COMP005 trial met its primary endpoint at week 6, with a 3.6-point difference on the Montgomery-Åsberg Depression Rating Scale versus placebo, though neither drug is FDA-approved.
Australia is the only country where MDMA is legal for prescription therapy, under the Therapeutic Goods Administration Authorised Prescriber scheme established in July 2023 for post-traumatic stress disorder. In the United States, MDMA remains a federal Schedule I controlled substance without state or federal therapeutic access outside clinical trials.
Psilocybin is not approved by the FDA and remains a federal Schedule I substance, but state-regulated administration is lawful in Oregon and Colorado. Oregon Measure 109 opened licensed service centers in 2023, and Colorado began licensing natural medicine healing centers in 2025 for supervised adult use without requiring a medical diagnosis.
Co-administering MDMA and psilocybin is not an approved or studied therapy protocol in clinical trials. This site has a separate safety guide on mixing MDMA and psilocybin.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.